Training in HFpEF-PH

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHeidelberg University

About this trial

Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved exercise capacity and health-related quality of life. Two meta-analyses have confirmed the beneficial effects in cardiorespiratory fitness and quality of life. The effects of exercise training on systolic and diastolic function remain inconclusive. Due to the positive results of exercise training in HFpEF, cardiac rehabilitation is recommended (Class I, level A) to be integrated into the overall provision of HF care. However, none of these studies focused on concomitant PH in HFpEF.

Exercise training in patients with pulmonary hypertension has already shown to improve exercise capacity, quality of life and peak oxygen consumption, which was confirmed by three meta-analyses and a Cochrane review. Though different diagnostic subgroups have already been enrolled in PH exercise training studies, they mainly included pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Data on combined PH and HFpEF is still lacking.

As recently pointed out by Arena et al. there may thus be an exercise training volume/intensity which may be detrimental to the RV in patients with HF and concomitant PH.

This study is sought to investigate whether a specialized training program is safe and tolerable and may improve exercise capacity, quality of life, hemodynamics, diastolic dysfunction and biomarkers in patients with PH and HFpEF.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female and male patients ≥18 years

WHO/NYHA functional class II - IV

Preserved left ventricular ejection fraction ≥50%

Patients receiving optimized therapy including intensified treatment with diuretics and who have been stable for 1 month before entering the study.

Disqualifiers

Pre-capillary pulmonary hypertension (Group I; Group III; Group IV; Group V according to PH guidelines)

Congenital or acquired severe valvular diseases (severe aortic stenosis or insufficiency, severe mitral valve stenosis or insufficiency)

Pregnancy or lactation

Walking disability

Trial design

Design model

Parallel

Treatments tested in this trial

  • Exercise rehabilitation

    Other intervention

    The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.

  • Standard treatment

    Other intervention

    Standard treatment during study duration

Treatment groups

90 Participants
are divided into 2 treatment groups
Group A: Exercise trainingActive comparator 1 intervention
Group B: Standard treatment (waiting group)Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

6-minute walking distance

Time frame
baseline to 15 weeks

Secondary outcomes

1

WHO functional class

Time frame
baseline to 15 weeks
2

Quality of life physical component scale SF-36

Time frame
baseline to 15 weeks
3

Quality of life mental component scale SF-36

Time frame
baseline to 15 weeks
4

peak oxygen consumption

Time frame
baseline to 15 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: